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a b s t r a c t
Reversed-phase high-performance liquid chromatography (RP-HPLC) was compared with the classical
Steelman–Pohley bioassay (BA), based on animal use, for the determination of human follicle-stimulating
hormone (hFSH) biological activity. A linear relationship (BAIU =0.9925RP-HPLCIU −1.3165)with a highly




rations of different origins. Themean difference between the bioactivity predicted fromRP-HPLC data via
this equation and the mean of the bioactivities obtained with the two methods for six other hFSH prepa-
rations was −1.4%, with a 95% conﬁdence interval of −9.3 to +6.6%. The precision of these parameters
was 1.63% and 2.82%, respectively. These results demonstrate that RP-HPLC is a viable physical–chemical







An important aspect in the quality control of therapeutic pro-
eins is the assessment of their biological activity. For this purpose,
nimal models are most commonly used. Considering the ethical
nd political pressures on the use of animals and the nature of
he assay, which can be imprecise and is in general costly, there
s clearly a need for alternative assays that reduce the use of and/or
eplace such tests [1–4].
In this context, several physical–chemical methods have been
eported in the literature as potential alternative assays for deter-
ining the biological activity of different proteins with greater
recision and accuracy. As a case in point, size-exclusion high-
erformance liquid chromatography (HPSEC) was shown to be
dequate for the determination of the potency of human growth
ormone (hGH) [5,6] and this assay has been adopted by the prin-
ipal pharmacopoeias as an alternative to the in vivo bioassay
erformed in hypophysectomized rats or dwarf “little” mice [7,8].
imilarly, a reversed-phase HPLC method (RP-HPLC) in combina-
ion with HPSEC was shown to correlate signiﬁcantly with the in
ivo bioassay for evaluating the potency of recombinant human
ranulocyte colony-stimulating factor (rhG-CSF) [9].
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In the case of glycoproteins, pituitary hormones included, the
replacement of tests based on animal use with physical–chemical
methods is particularly challenging, especially considering the
complexity of these molecules and the heterogeneity of their gly-
cosylation. While some advocate the possibility of equivalency or
at least complementarity between physical–chemical and in vivo
methods [10], others believe that it is not possible to corre-
late a parameter derived from a global systemic measurement
with a more targeted determination of an analyte [11]. Efforts
have been made to develop tests for potency assessment that
avoid the use of animals. There are already in the literature
physical–chemicalmethods showingagoodcorrelationwith in vivo
assays [12–17]. RP-HPLC was proposed as a possible alternative
to the normocythaemic mice bioassay for the potency assessment
of recombinant human erythropoietin [12]. The in vivo bioactivity
of a therapeutic glycoprotein, human follicle-stimulating hormone
(hFSH), used in the treatment of human infertility [18–20], could
be predicted by using quantitative charge-based separation meth-
ods like isoelectric focusing and capillary zone electrophoresis.
A highly signiﬁcant correlation between the isoform distribution
and the in vivo bioactivity was demonstrated by Mulders et al.
[13,14] and by Storring et al. [15]. Still with regard to hFSH,
Open access under the Elsevier OA license.HPSEC has been successfully employed instead of the bioassay
in the production phase, for batch-to-batch consistency assess-
ment and for precise drug delivery, an essential requirement for
the achievement of the treatment objectives in clinical practice
[16,17].




















































Inter-day hFSH determination of preparations of different origins, by RP-HPLC.
Preparation FSH contenta (g/vial) RSDb (%)
rhFSH-A 5.5 ± 0.32 5.8
rhFSH-B 9.8 ± 0.41 4.2
phFSH-C 4.8 ± 0.03 1.7
phFSH-D 6.7 ± 0.12 1.6
uhFSH-E 5.2 ± 0.30 5.882 B.E. Almeida et al. / Journal of Pharmaceut
Considering the advantages of speed, simplicity, and reliability
f RP-HPLC, we chose to use a RP-HPLC method in this work for the
uantiﬁcation of different preparations of hFSH (CHO-, pituitary-
nd urinary-derived) in order to evaluate its applicability as a less
xpensive and more ﬂexible alternative method to the classical
teelman and Pohley bioassay based on the rat ovarian weight gain
ethod [21].
. Materials and methods
.1. Chemicals and reagents
Water was obtained from a Milli-Q Plus water-puriﬁcation
ystem (Millipore, Bedford, MA, USA). Acetonitrile (HPLC-grade,
allinckrodt Baker) was purchased from Hexis (São Paulo, Brazil).
ll other chemicals were analytical reagent grade, purchased from
erck (São Paulo, Brazil) and Sigma (St. Louis, MO, USA).
.2. Hormone preparations
Thirteen hFSH preparations were analyzed in this work:
ve recombinant preparations, CHO (Chinese hamster ovary)-
erived (rhFSH-A, rhFSH-B, rhFSH-J, rhFSH-K, rhFSH-L), two
ituitary (phFSH-C and phFSH-D), ﬁve urinary preparations
uhFSH-E, uhFSH-F, uhFSH-G, uhFSH-H, uhFSH-I) and the Inter-
ational Standard of rhFSH-WHO 92/642. For the biological
ssays, two standards were utilized: the International Standard
f follicle-stimulating hormone (FSH) Recombinant, Human for
ioassay (WHO 92/642), and the International Standard of follicle-
timulating hormone (FSH) Pituitary, Human for Bioassay (WHO
3/575).
These preparations were obtained from: Aker University Hos-
ital (Oslo, Norway), Ferring GmbH (Kiel, Germany), Institut
iochimique S.A. (IBSA) (Lugano, Switzerland), Laboratoires Serono
.A. (Aubonne, Switzerland), National Hormone and Pituitary Pro-
ram (Torrance, CA, USA) and N.V. Organon (Oss, Netherlands). The
HO International Standards were from the National Institute for
iological Standards and Control (NIBSC, South Mimms, UK).
.3. Reversed-phase high-performance liquid chromatography
RP-HPLC)
RP-HPLC was carried out with a Shimadzu Model SCL-10AHPLC
pparatus with a SPD-10AV UV detector using a C4-Grace Vydac
Separations Group, Hesperia, CA, USA) 214 TP 54 column
25cm×4.6mm I.D., pore diameter of 300 A˚ and particle diameter
f 5m), coupled to a guard column (GraceVydac 214 FSK54),with
silica pre-column (packed with LiChrosorb Si 60, 7.9–12.4m,
erck, Darmstadt, Germany) located between the pump and the
njector. The column temperature was maintained at 25 ◦C. Detec-
ion was by UV at 220nm and quantiﬁcation was achieved by
eak area determination reported to the International Standard
f rhFSH-WHO 92/642. Gradient solutions A and B were utilized,
olution A being ammonium phosphate buffer (pH 8.6; 0.05M) and
olution B acetonitrile. The elution was performed with a linear
radient from A:B (85:15, v/v) to A:B (50:50, v/v) over 40min, at a
ow-rateof 0.5ml/min.Aliquots of 5–10l of phFSHand20–100l
f rhFSH or uhFSH were, in general, processed.
.4. High-performance size-exclusion chromatography (HPSEC)HPSEC was carried out with the same Shimadzu apparatus, pro-
essing 20–50l of rhFSH on a Tosohaas (Montgomeryville, PA,
SA) G2000 SW column (60 cm×7.5mm I.D. particle size of 10m
nd pore size of 125 A˚) coupled to a 7.5 cm×7.5mm I.D. SW guarduhFSH-F 10.3 ± 0.27 2.6
a Mean± standard deviation (n=4).
b Relative standard deviation.
column. The mobile phase was 0.15M NaCl, sodium phosphate
buffer (pH 7.0; 0.02M), with a ﬂow rate of 1.0ml/min.
2.5. Biological assays
hFSH activity was determined by the rat ovarian weight gain
method of Steelman and Pohley [21] and the assay was conducted
in accordance with the national protection laws on animal wel-
fare. Brieﬂy, 19–22 day old Sprague–Dawley immature female rats
received once a day, subcutaneously, over three consecutive days,
0.5, 1 and 3 IU of hFSH. Autopsy was performed on the fourth day
(72h after the ﬁrst injection). The ovaries were removed, dissected
free of surrounding tissue, and weighed. The in vivo FSH bioactivity
was calculated against the recombinant hFSH International Stan-
dard WHO 92/642 in the case of urinary- and CHO-derived hFSH or
against the pituitary hFSH International Standard WHO 83/575, in
the case of pituitary-derived samples.
Statistical analysis of the assay data was carried out according
to Finney, by parallel line methods (3×3), using PLA 2.0 software
(Stegmann System-beratung, Rodgau, Germany).
2.6. Statistical methods
The comparison between bioassay and RP-HPLC data was made
by linear regression analysis and the agreement between the two
methods was evaluated as described by Bland and Altman [22].
Differences betweenmeanswere assessed by using Student’s t-test
(two-sided).
3. Results
The content of hFSH (g per vial) in 6 preparations of differ-
ent origins, CHO- (A and B), pituitary- (C and D) and urinary- (E
and F) derived, was determined by a previously reported RP-HPLC
technique (Table 1) [23]. An inter-day (n=4) inter-ampoule vari-
ation<6% was observed. Considering the lack of ofﬁcial standards
suitable for physical–chemical testing, we reported our determi-
nations relative to the hFSH international recombinant reference
standard for biological assays from the National Institute for Bio-
logical Standards and Control (WHO 92/642), which presented the
RP-HPLC chromatographic proﬁle shown in Fig. 1A. It is notewor-
thy that the hFSH peak area shown in the ﬁgure, later proved to
correspond to 2g of pure recombinant hFSH, as expected. This
standard reference preparation could only be utilized for quantita-
tive analysis carried out by RP-HPLC, considering the presence, in
this preparation, of a high content (200:1) of human serum albu-
min (HSA), which completely obscures the peak of hFSH in HPSEC
(Fig. 1B).
RP-HPLC proﬁles of the three groups of hFSH preparations
analyzed in this study are shown in Fig. 2. Highly signiﬁcant differ-
ences (p<0.001) in FSH retention time (tR) between recombinant
(tR =26.42±0.23, n=8), pituitary (tR =25.19±0.15, n=8) and uri-
nary (tR =24.46±0.22, n=8) preparations were found, reﬂecting
differences in the carbohydrate moieties. The peak with tR of


























pig. 1. HPLC proﬁle of 2g of the recombinant hFSH reference standard for biol
reparation that is free of HSA, run under identical conditions is indicated by the ar
7min corresponds to the excipient present in different amounts
n the analyzed samples.
The potency estimates (International Units, IU per vial), by in
ivo biological assay for recombinant and urinary preparations
ere determined against recombinant hFSH reference standard,
HO 92/642, while the pituitary preparations were determined
gainst pituitary referencepreparationWHO83/575 (Table 2). For a
etter understanding and easier comparison, in the same Table the
FSHcontent thatwasdeterminedbyRP-HPLC ingwasexpressed
n IU because unitage system is still the one most commonly used
n clinical practice. An average hFSH recovery of 108.3±11.63% of
he nominal content was estimated on the basis of the bioassay,
s compared to an average recovery of 111.9±20.09% by RP-HPLC
Table 2). When the potency determination by bioassay (BAIU) was
ompared with hFSH quantiﬁcation by RP-HPLC (RP-HPLCIU), a lin-
ar relation was found (BAIU =0.9925RP-HPLCIU −1.3165), with
highly signiﬁcant degree of correlation (r=0.9371; p<0.0001;
=24).
To evaluate the potential of RP-HPLC for accurately predicting
he in vivo bioactivity according to Bland–Altman analysis [22], a
omparison between the in vivo bioactivity estimated by RP-HPLC
rom the above equation with that estimated by the Steelman and
ohley bioassay was carried out. Six samples that had not been
sed for the correlation analysis were employed (Table 3). This
nalysis revealed a mean percentage difference (d¯) between the
redicted and the mean of the bioactivities obtained by the twoassays (WHO 92/642). (A) RP-HPLC. (B) HPSEC. The retention time of an rhFSH
methods of−1.35%,wellwithin the 95% conﬁdence limits (d¯ ± 2SD)
of −9.3 to +6.6% (Fig. 3). A Student’s t-test performed on the aver-
age± SD of the in vivo and predicted bioactivities indicated that
the calculated t-value of 0.037 is much smaller than the theoretical
t-value of 2.57, at the 0.05 signiﬁcance limit for 5 degrees of free-
dom, indicating that the results of the two methodologies were not
signiﬁcantly different. To evaluate how precise the determinations
were, the standard error of d¯, deﬁned as
√
SD2/n and the stan-
dard error of d¯ ± 2SD, deﬁned as
√
3SD2/n, were determined as







, for the lower limit of agreement (LL) and
for the upper limit of agreement (UL) were calculated. All of these
statistical parameters are shown in Table 4.
4. Discussion
Based on the ﬁndings of the present work, it can be con-
cluded that physical–chemical analysis, via RP-HPLC, is indeed a
viable alternative to in vivo bioassay for determining hFSH potency.
This alternative can be useful, for example, in quality control of
internet-obtained pharmaceuticals, being possibly able to detect
counterfeited and/or substandard drugs [24]. Further work should
be carried out in this direction and the current results should be
complemented with samples of this type. Mass spectrometry (MS)









Cig. 2. RP-HPLC proﬁle of different hFSH preparations: rhFSH-A (5.2g); rhFSH-B (
valuationwould also be very interesting, especially for identifying
lycosylation sites.
The RP-HPLC methodology employed, which was previously
stablished in our laboratory and validated with respect to accu-
acy, precision, linearity and sensitivity, is, as far as we know,
nique in the literature in its capacity to analyze intact hFSH, i.e.,
FSH in its heterodimeric form [23]. Thanks to this methodology,
able 2
omparison between the quantiﬁcation of hFSH preparations via in vivo bioassay and by







a Based on declared content.
b RP-HPLC determinations expressed in IU considering 13,800 IU/mg to be the potencyg); phFSH-C (1.2g); phFSH-D (1.7g); uhFSH-E (4.7g); uhFSH-F (11.1g).
we could also use an international standard of hFSH for biologi-
cal assay (WHO 92/642) as the standard in our physical–chemical
assay. Analysis of this standard via RP-HPLC demonstrated that the
large amount of HSA present in the ampoule did not elute out of the
column, under our running conditions, not interfering thus with
hFSH determination, in a preparation in which it represents less
than 1% of the total mass.
RP-HPLC.







of rhFSH-WHO 92/642 and 19184 IU/mg the potency of phFSH-WHO 83/575.
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Table 3
Comparison between the biological activity determined by the in vivo bioassay and predicted by the equation via RP-HPLC analysis.
Preparation Biological activity
determined by in vivo
bioassay (1) (IU/vial)
Biological activity
predicted by RP-HPLC (2)
(IU/vial)




biological activity d (IU)
Difference between
predicted and mean
biological activity d (%)
uhFSH-G 68.0 58.0 63.0 −5.0 −7.9
uhFSH-H 150.3 164.2 157.3 +6.9 4.4
uhFSH-I 74.0 70.3 72.2 −1.9 −2.6
rhFSH-J 119.0 116.4 117.7 −1.3 −1.1
rhFSH-K 116.6 114.2 115.4 −1.2 −1.0
rhFSH-L 115.8 116.1 116.0 +0.1 0.09

















tFig. 3. Comparison between the RP-HPLC-predicted and in viv
Highly signiﬁcant differences in FSH RP-HPLC retention time
ere found between recombinant, pituitary and urinary hFSH,
robably reﬂecting the effect of structural differences in the
arbohydrate moiety on the hydrophobicity of the glycoprotein
olecule. Analogous observations were made for the other two
ituitary glycoprotein hormones, TSH [25,26] and hLH [27]. The
ame RP-HPLC analytical approach was also shown to be useful for
he detection of the presence of undesirable free subunits in prepa-
ations of the three glycoprotein hormones (hFSH, hTSH and hLH).
his is an important pharmaceutical control, considering that the
ull hormonal activity is due only to the intact heterodimeric form
28].
A highly signiﬁcant correlation (p<0.0001) was found between
he RP-HPLC results and the in vivo assay when analyzing recom-
inant, pituitary and urinary hFSH samples (see Table 2). This
able 4
tatistical parameters, determined according to Bland and Altman [22], comparing
he values of in vivo bioactivity with those predicted via RP-HPLC determinations.
Parameter Determined value (%)
Mean difference (d¯) −1.35
Standard deviation (SD) 3.99




























−0.65 to +13.9ctivity by plotting their percent difference against their mean.
analysis, however, did not include partly-degraded samples which
could present different degrees of in vivo activity. In this case,
RP-HPLC should be able to detect the product alterations that
cause loss of activity. For the validation of the regression model,
Bland–Altman analysis [22]was carried out by utilizing six samples
of hFSH preparations that had not been used to construct the corre-
lation curve. For these six samples, the RP-HPLC-predicted and the
in vivo bioassay data were not signiﬁcantly different. An acceptable
agreement (bias <1.5%)between the twomethodologieswas found,
the potency estimatedby the formermethodbeingno less than85%
and no more than 109% of that estimated by the latter method. We
can also observe that most of the calculated statistical parameters
(see Table 4) were of the same order or even better than those
found in the literature for analogous studies [13,14]. It is important
to emphasize that this type of validation conforms to the guide-
linesof the “EuropeanCentre forValidationofAlternativeMethods”
(ECVAM) of the European Commission. It is recommended that
this procedure for comparing data from different methods be used
whenever possible [14,15,29].
Even though the RP-HPLC methodology is potentially capable
of discriminating between different hFSH isoforms [30], we did not
develop this possibility further, as has been done, for example, by
Mulders et al. [13] andStorring et al. [15], applying either isoelectric
focusing or capillary zone electrophoresis to evaluate the bioactiv-
ity of preparations consisting of different isoforms. The fact that,
on a simple mass basis, our methodology was also able to predict
biological activities with reasonable accuracy could be due to the
fact that glycan or isoformdistribution in general is not remarkably
different between the various preparations tested or, alternatively,
that the isoformswith the greatest bioactivity variation are present











































[86 B.E. Almeida et al. / Journal of Pharmaceut
ther studieswhere bioactivity assessment for hFSHwas also based
n mass determination, such as those of Driebergen et al. [16] and
assett [17].
A single type of physical–chemical analysis obviously cannot
irror all aspects of the in vivo biological activity of a hormone.
n agreement with the “consistency approach” [29,31,32], which
mplies the use of speciﬁc tests to demonstrate equivalence of
product with another of proven efﬁcacy, there is a tendency
o accept alternative assays that could complement the classical
n vivo bioassay. These can be used in routine determinations, after
he initial validationof theprocessdevelopment inwhichaclassical
n vivo bioassay is recommended.
In conclusion, the employment of non-animal alternatives, such
s RP-HPLC, can reduce the number of animals currently used to
ssure quality and efﬁcacy of a pharmaceutical product. In this
egard, the results of the present pilot study pave the way for pos-
ible replacement of in vivo bioassays in quality control protocols
or the assessment of hFSH potency.
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07/56094-2) andby theNational ResearchCouncil (CNPq), Brasilia,
razil (PQ 303839/2008-2 and PQ 3000473/2009-5).
eferences
[1] G. Miethe, Possibilities of replacing and reducing animal tests in the phar-
macopoeias: an evaluation of unused methods and proposals for change,
ATLA-Altern. Lab. Anim. 30 (2002) 229–240.
[2] C.F.M. Hendriksen, Reduction of numbers of animals used in the quality control
of biologicals, ATLA-Altern. Lab. Anim. 32 (2004) 53–58.
[3] B. Metz, F. Brunel, C. Chamberlin, J. van der Gun, M. Halder, W. Jiskoot, G.
Kersten, O. van Opstal, J.W. Petersen, S.D. Ravetkar, K. Redhead, M. Schwanig,
E.S. Wilhelmsen, W.F. Vann, C. Hendriksen, The potential of physicochemical
and immunochemical assays to replace animal tests in the quality control of
toxoid vaccines. The report and recommendations of ECVAM workshop 61,
ATLA-Altern. Lab. Anim. 35 (2007) 323–331.
[4] S. Obora, T. Kurosawa, Implementation of the Three Rs in biomedical research –
has the turn of the century turned the tide? ATLA-Altern. Lab. Anim. 37 (2009)
197–207.
[5] R.M. Riggin, C.J. Shaar, G.K. Dorulla, D.S. Lafeber, D.J. Miner, High-performance
size-exclusion chromatography determination of the potency of biosyn-
thetic human growth hormones products, J. Chromatogr. 435 (1988)
307–318.
[6] A.F. Bristow, S.L. Jeffcoate, Analysis of therapeutic growth hormone prepara-
tions: report of an interlaboratory collaborative study on growth hormone
assay methodologies, Biologicals 20 (1992) 221–231.
[7] A.E. Wilhelmi, Growth hormone bioassay, in: S.A. Berson, R.S. Yalow (Eds.),
Methods in Investigative and Diagnostic Endocrinology, North Holland, Ams-
terdam, 1973, pp. 296–302.
[8] M.H. Bellini, P. Bartolini, In vivo bioassay for the potency determination of
human growth hormone in dwarf “little” mice, Endocrinology 132 (1993)
2051–2055.
[9] S.L. Dalmora, S.M.K.Masiero, P.R. deOliveira,M.D. Sangoi, L. Brum,Validation of
anRP-LCmethodandassessmentof rhG-CSF inpharmaceutical formulationsby
liquid chromatography and biological assay, J. Liq. Chromatogr. Relat. Technol.
29 (2006) 1753–1767.
10] M. Halder, C.F.M. Hendriksen, K. Cussler, M. Balls, ECVAM’s contributions to
the implementation of the Three Rs in the production and quality control of
biologicals, ATLA-Altern. Lab. Anim. 30 (2002) 93–108.
11] J.M. Spieser, Alternatives to animal testing: new approaches in the develop-
ment and control of biologicals, in: Proceedings of International Symposium
[d Biomedical Analysis 54 (2011) 681–686
organized by the European Directorate for the Quality of Medicines & Health-
Care (EDQM), Council of Europe in Close Co-operation with the Ministry of
Health and Social Welfare of Croatia, Dubrovnik, Croatia, 2008, pp. 37–38.
12] T. Barth, M.D. Sangoi, L.M. da Silva, R.M. Ferretto, S.L. Dalmora, Assessment
of rhEPO in pharmaceutical formulations by a reversed-phase liquid chro-
matography method and bioassay, J. Liq. Chromatogr. Relat. Technol. 30 (2007)
1277–1288.
13] J.W.Mulders,M. Derksen, A. Swolfs, F.Maris, Prediction of the in vivo biological
activity of human recombinant follicle stimulating hormone using quantitative
isoelectric focusing, Biologicals 25 (1997) 269–281.
14] J.W.Mulders, H.Wijn, F. Theunissen, P.Machielsen, P. Janssen, Prediction of the
in vivo biological activity of human recombinant follicle stimulating hormone
usingquantitative isoelectric focusing.Optimizationof themodel, Pharm.Phar-
macol. Commun. 5 (1999) 51–55.
15] P.L. Storring,R.E.GainesDas, J.W.Mulders,M.Halder, Physicochemicalmethods
for predicting the biological potency of recombinant follicle stimulating hor-
mone: an international collaborative study of isoelectric focusing and capillary
zone electrophoresis, Biologicals 30 (2002) 217–234.
16] R. Driebergen, G. Baer, Quantiﬁcation of follicle stimulating hormone (fol-
litropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr.
Med. Res. Opin. 19 (2003) 41–46.
17] R. Bassett, Continued improvements in thequality andconsistencyof follitropin
alfa, recombinant human FSH, Reprod. Biomed. 10 (2005) 169–177 (online).
18] E. Loumaye, R. Campbell, J. Salat-Baroux, Human follicle-stimulating hormone
produced by recombinant DNA technology: a review for clinicians, Hum.
Reprod. Update 1 (1995) 188–199.
19] N.S.Macklon, R.L. Stouffer, L.C. Giudice, B.C. Fauser, The science behind 25 years
of ovarian stimulation for in vitro fertilization, Endocr. Rev. 27 (2006) 170–207.
20] E. Bosch, Recombinant human follicular stimulating hormone and recombi-
nant human luteinizing hormone in a 2:1 ratio combination. Pharmacological
characteristics and clinical applications, Expert Opin. Biol. Ther. 10 (2010)
1001–1009.
21] S.L. Steelman, F.M. Pohley, Assay of the follicle stimulating hormone based
on the augmentation with human chorionic gonadotropin, Endocrinology 53
(1953) 604–616.
22] J.M. Bland, D.G. Altman, Statistical methods for assessing agreement between
two methods of clinical measurement, Lancet 1 (1986) 307–310.
23] R.F. Loureiro, J.E. Oliveira, P.A. Torjesen, P. Bartolini, M.T.C.P. Ribela, Analysis
of intact human follicle-stimulating hormone preparations by reversed-phase
high-performance liquid chromatography, J. Chromatogr. A1136 (2006) 10–18.
24] B. Baert, B. De Spiegeleer, Quality analytics of internet pharmaceuticals, Anal.
Bioanal. Chem. 398 (2010) 125–136.
25] J.E. Oliveira, F. Mendonca, C.N. Peroni, P. Bartolini, M.T.C.P. Ribela, Determi-
nation of Chinese hamster ovary cell-derived recombinant thyrotropin by
reversed-phase liquid chromatography, J. Chromatogr. B 787 (2003) 345–355.
26] F. Mendonca, J.E. Oliveira, P. Bartolini, M.T.C.P. Ribela, Two-step chro-
matographic puriﬁcation of recombinant human thyrotrophin and its
immunological, biological, physico-chemical and mass spectral characteriza-
tion, J. Chromatogr. A 1062 (2005) 103–112.
27] B.E. Almeida, J.E. Oliveira, C.M. Carvalho, S.L. Dalmora, P. Bartolini, M.T.C.P.
Ribela, Analysis of human luteinizing hormone and human chorionic
gonadotropin preparations of different origins by reversed-phase high-
performance liquid chromatography, J. Pharm. Biomed. Anal. 53 (2010) 90–97.
28] C.M. Carvalho, J.E. Oliveira, B.E. Almeida, E.K.M. Ueda, P.A. Torjesen, P. Bartolini,
M.T.C.P. Ribela, Efﬁcient isolation of the subunits of recombinant and pituitary
glycoprotein hormones, J. Chromatogr. A 1216 (2009) 1431–1438.
29] B. Garthoff, C.F.M. Hendriksen, A. Bayol, D. Goncalves, A. Grauer, R. Deleeuw, J.
Vannoordwijk, M. Pares, R. Pirovano, M. Rieth, H. Ronneberger, J.M. Spieser, P.
Storring, K. Vosbeck, H. Weichert, Safety and efﬁcacy testing of hormones and
related products – the report and recommendations of Ecvam workshop-9,
ATLA-Altern. Lab. Anim. 23 (1995) 699–712.
30] M.T.C.P. Ribela, P.W. Gout, J.E. Oliveira, P. Bartolini, HPLC analysis of human
pituitary hormones for pharmaceutical applications, Curr. Pharm. Anal. 2
(2006) 103–126.
31] C.F.M. Hendriksen, J.L. Arciniega, L. Bruckner, M. Chevalier, E. Coppens, J.
Descamps, M. Duchene, D.M. Dusek, M. Halder, H. Kreeftenberg, A. Maes, K.
Redhead, S.D. Ravetkar, J.M. Spieser, H. Swam, The consistency approach for
the quality control of vaccines, Biologicals 36 (2008) 73–77.
32] C.F.M. Hendriksen, Replacement, reduction and reﬁnement alternatives to
animal use in vaccine potency measurement, Expert Rev. Vaccines 8 (2009)
313–322.
